Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: Current results of a multicenter trial

German Myeloma Treatment Group

doi:10.1159/000216820

Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: Current results of a multicenter trial

German Myeloma Treatment Group

Division of Hematology & Medical Oncology

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

277 untreated multiple myeloma patients of stage I (n = 33), II (n=106) and III (n=138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n=14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-a maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was >36 months in stage II and 11 months in stage III patients.

Original language	English (US)
Pages (from-to)	458-460
Number of pages	3
Journal	Oncology Research and Treatment
Volume	13
Issue number	6
DOIs	https://doi.org/10.1159/000216820
State	Published - 1990

Keywords

Induction therapy
Maintenance treatment
Multiple myeloma

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1159/000216820

Fingerprint Dive into the research topics of 'Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: Current results of a multicenter trial'. Together they form a unique fingerprint.

Cite this

Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma : Current results of a multicenter trial. / German Myeloma Treatment Group.

In: Oncology Research and Treatment, Vol. 13, No. 6, 1990, p. 458-460.

Research output: Contribution to journal › Article › peer-review

@article{0a4f7c66a0694cccab05e98e839c7089,

title = "Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: Current results of a multicenter trial",

abstract = "277 untreated multiple myeloma patients of stage I (n = 33), II (n=106) and III (n=138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n=14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-a maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was >36 months in stage II and 11 months in stage III patients.",

keywords = "Induction therapy, Maintenance treatment, Multiple myeloma",

author = "{German Myeloma Treatment Group} and D. Peest and H. Deicher and R. Coldewey and R. Leo and R. Bartl and H. Bartels and Braun, {H. J.} and {von Broen}, {I. M.} and Fischer, {J. T.} and M. Gramatzki and R. Hein and R. Henke and L. Hoffmann and Kreuser, {E. D.} and Maier, {W. D.} and Meier, {C. R.} and J. Oertel and M. Planker and Reinhold, {H. M.} and E. Sch{\"a}fer and E. Schumacher and K. Schumacher and J. Selbach and M. Stennes and W. Stenzinger and C. Tirier and H. Wagner and Weh, {H. J.} and J. Wysk",

year = "1990",

doi = "10.1159/000216820",

language = "English (US)",

volume = "13",

pages = "458--460",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "6",

}

TY - JOUR

T1 - Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma

T2 - Current results of a multicenter trial

AU - German Myeloma Treatment Group

AU - Peest, D.

AU - Deicher, H.

AU - Coldewey, R.

AU - Leo, R.

AU - Bartl, R.

AU - Bartels, H.

AU - Braun, H. J.

AU - von Broen, I. M.

AU - Fischer, J. T.

AU - Gramatzki, M.

AU - Hein, R.

AU - Henke, R.

AU - Hoffmann, L.

AU - Kreuser, E. D.

AU - Maier, W. D.

AU - Meier, C. R.

AU - Oertel, J.

AU - Planker, M.

AU - Reinhold, H. M.

AU - Schäfer, E.

AU - Schumacher, E.

AU - Schumacher, K.

AU - Selbach, J.

AU - Stennes, M.

AU - Stenzinger, W.

AU - Tirier, C.

AU - Wagner, H.

AU - Weh, H. J.

AU - Wysk, J.

PY - 1990

Y1 - 1990

N2 - 277 untreated multiple myeloma patients of stage I (n = 33), II (n=106) and III (n=138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n=14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-a maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was >36 months in stage II and 11 months in stage III patients.

AB - 277 untreated multiple myeloma patients of stage I (n = 33), II (n=106) and III (n=138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n=14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-a maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was >36 months in stage II and 11 months in stage III patients.

KW - Induction therapy

KW - Maintenance treatment

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0025602136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025602136&partnerID=8YFLogxK

U2 - 10.1159/000216820

DO - 10.1159/000216820

M3 - Article

C2 - 2092283

AN - SCOPUS:0025602136

VL - 13

SP - 458

EP - 460

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 6

ER -